Commentary: The epidemiology of self-deprecation

International Journal of Epidemiology

Volumn 31, Issue 6, 2002, Pages 1124-1127

  Nieto, F J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HOMOCYSTEINE;

ANALYTIC METHOD; CIGARETTE SMOKING; DATA ANALYSIS; ESTROGEN DEFICIENCY; EXPOSURE; GENE; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMOBILIZATION; INCIDENCE; ISCHEMIC HEART DISEASE; JOB SATISFACTION; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NOTE; PATHOGENESIS; POLICY; POVERTY; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; RISK FACTOR; SELF CONCEPT; SOCIAL PSYCHOLOGY; THROMBOSIS;

ATTITUDE OF HEALTH PERSONNEL; CORONARY DISEASE; EVIDENCE-BASED MEDICINE; HUMANS; RISK FACTORS;

EID: 0036990195     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/31.6.1124     Document Type: Note

References (35)

1. Susser M. Epidemiology today: 'a thought-tormented world'. Int J Epidemiol 1989;18:481-88.
2. Susser M, Susser E. Choosing a future for epidemiology: I. Eras and paradigms. Am J Public Health 1996;86:668-73.
3. Susser M, Susser E. Choosing a future for epidemiology: II. From black box to Chinese boxes and eco-epidemiology. Am J Public Health 1996;86:674-77.
4. Pearce N. Traditional epidemiology, modern epidemiology, and public health. Am J Public Health 1996;86:678-83.
5. Shy CM. The failure of academic epidemiology: witness for the prosecution. Am J Epidemiol 1997;145:479-84; discussion 485-87.
6. Charlton BG. Should epidemiologists be pragmatists, biostatisticians, or clinical scientists? Epidemiology 1996;7:552-54.
7. Charlton BG. The scope and nature of epidemiology. J Clin Epidemiol 1996;49:623-26.
8. Skrabanek P. The epidemiology of errors. Lancet 1993;342:1502.
9. Wildavsky A. But is it True? A Citizen's Guide to Environmental Health and Safety Issues. Cambridge, MA: Harvard University Press, 1995.
10. Tauber G. Epidemiology faces its limits. Science 1995;269:164-69.
11. Beaglehole R, Magnus P. The search for new risk factors for coronary heart disease: occupational therapy for epidemiologists? Int J Epidemiol 2002;31:1117-22.
12. Magnus P, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: time to end the 'only-50%' myth. Arch Intern Med 2001;161:2657-60.
13. Strong JP, McGill HC, Jr. The pediatric aspects of atherosclerosis. J Atheroscler Res 1969;9:251-65.
14. Strong JP, Malcom GT, McMahan CA et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999;281:727-35.
15. Saikku P. The epidemiology and significance of Chlamydia pneumoniae. J Infect 1992;25(Suppl.1):27-34.
16. Shapiro S. Meta-analysis/shmeta-analysis. Am J Epidemiol 1994; 140:771-78.
17. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ 1998;316:140-44.
18. Leinonen M, Saikku P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2002;2:11-17.
19. Nieto FJ. Infections and atherosclerosis: new clues from an old hypothesis? Am J Epidemiol 1998;148:937-48.
20. O'Connor S, Taylor C, Campbell LA, Epstein S, Libby P. Potential infectious etiologies of atherosclerosis: a multifactorial perspective. Emerg Infect Dis 2001;7:780-88.
21. Kalayoglu MV, Byrne GI. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 1998;66:5067-72.
22. Kalayoglu MV, Hoerneman B, LaVerda D, Morrison SG, Morrison RP, Byrne GI. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis 1999;180:780-90.
23. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999;103:747-53.
24. Muhlestein JB, Anderson JL, Hammond EH et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-36.
25. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998;5:229-32.
26. Maxwell SR. Coronary artery disease-free radical damage, anti-oxidant protection and the role of homocysteine. Basic Res Cardiol 2000;95(Suppl.1):165-71.
27. Tracy RP. Epidemiological evidence for inflammation in cardiovascular disease. Thromb Haemost 1999;82:826-31.
28. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-26.
29. Wick G, Perschinka H, Xu Q. Autoimmunity and atherosclerosis. Am Heart J 1999;138(5Pt 2):S444-49.
30. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14:32-38.
31. Rothman KJ, Adami HO, Trichopoulos D. Should the mission of epidemiology include the eradication of poverty? Lancet 1998; 352:810-13.
32. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. 1982. JAMA 1997;277:582-94.
33. Feinleib M. New directions for community intervention studies. Am J Public Health 1996;86:1696-98.
34. Salonen JT. Did the North Karelia project reduce coronary mortality? Lancet 1987;ii:269.
35. McCormick J, Skrabanek P. Coronary heart disease is not preventable by population interventions. Lancet 1988;ii:839-41.